Clinical Trial

A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 18, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study will be conducted in about 51 participants in total. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor efficacy of Hemay181 in patients with advanced solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-27; most recent amendment 2025-04-17.
Status change: Not Yet Recruiting → Recruiting 2024-03-05
Trial Details
NCT Number NCT05749432
Lead Sponsor Ganzhou Hemay Pharmaceutical Co., Ltd
Conditions Solid Tumor
Enrollment 51 participants
Start Date 2023-03-20
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-18